Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Yvette C, Tanhehco"'
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Recent advances in managing Sickle Cell Disease (SCD) significantly improved patient survival and quality of life. Disease-modifying drug therapies such as hydroxyurea, L-glutamine, voxelotor, and crizanlizumab reduce pain crises and severe complicat
Externí odkaz:
https://doaj.org/article/07378119d7ab44d484e81a3315d94a62
Autor:
Yvette C Tanhehco
Publikováno v:
Cell and Gene Therapy Insights. :271-277
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c740ebeb992a89f709ee199df308ed0
https://doi.org/10.18609/cgti.2023.043
https://doi.org/10.18609/cgti.2023.043
Autor:
Yvette C. Tanhehco, Patricia A. Shi
Publikováno v:
Practical Transfusion Medicine. :409-416
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32e7ae0b4fea3b37bcb4fdf50c873655
https://doi.org/10.1002/9781119665885.ch34
https://doi.org/10.1002/9781119665885.ch34
Autor:
Yvette C. Tanhehco
Publikováno v:
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 61(5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3471b500891f353bcb87b4131eb152e
https://pubmed.ncbi.nlm.nih.gov/36114123
https://pubmed.ncbi.nlm.nih.gov/36114123
Publikováno v:
Transfusion medicine reviews.
Blood Banking/Transfusion Medicine (BB/TM) specialists oversee all aspects of blood component transfusions and are often involved with apheresis, coagulation, and cellular therapy services as well. This study characterizes the BB/TM workforce to dete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a212da54cbc52f3312431ba935b3df3a
https://pubmed.ncbi.nlm.nih.gov/36411213
https://pubmed.ncbi.nlm.nih.gov/36411213
Autor:
Patrick, Trépanier, Diane, Fournier, Carl, Simard, Magali J, Fontaine, David, Stroncek, Minoko, Takanashi, David, McKenna, Joseph, Schwartz, Yvette C, Tanhehco, Jo-Anna, Reems, Silvia, Torrents, Gesine, Kogler, Stefanie, Liedtke, Martin, Giroux, Jelena L, Holovati, Isabelle, Louis, Arun, Prasath, Nicolas, Pineault, Renée, Bazin
Publikováno v:
TransfusionREFERENCES. 62(8)
The IL-3-pSTAT5 assay, a new, rapid, and standardized flow-cytometry-based assay may compensate for several limitations of the colony-forming unit (CFU) assay typically used for stem cell potency assessments of cord blood units (CBU). We performed an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20c30a5253b83a16736b6cf751f1d3cb
https://pubmed.ncbi.nlm.nih.gov/35770742
https://pubmed.ncbi.nlm.nih.gov/35770742
Autor:
Srivaths Poyyapakkam, Angela Treml, Yvette C. Tanhehco, Nicole D. Zantek, Sarita Joshi, Monica B. Pagano, Joseph E. Schwartz, Yanhua Li, Laura D. Stephens, Ileana Lopez-Plaza
Publikováno v:
Transfusion. 60:2432-2440
Background Entrustable professional activities (EPAs) are well-defined, executable, observable, and measurable activities that are performed by a trainee and can be performed independently as training progresses. The purpose of this study is to devel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd44ee73ec8dd4e51947b2609f269a98
https://doi.org/10.1111/trf.15983
https://doi.org/10.1111/trf.15983
Autor:
Yvette C. Tanhehco
Publikováno v:
Clinics in laboratory medicine. 41(4)
Red blood cell (RBC) transfusions are necessary to increase a patient's oxygen carrying capacity. The optimal transfusion trigger remains elusive, but a restrictive transfusion trigger of 7 g/dL has been shown in studies to reduce RBC transfusions wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c7b346a713e0384b057d3a2699d4d79
https://pubmed.ncbi.nlm.nih.gov/34689968
https://pubmed.ncbi.nlm.nih.gov/34689968
Autor:
Evan, Waldron, Yvette C, Tanhehco
Publikováno v:
Transfusion and Apheresis Science. 61:103566
Gene therapy will soon become the dominant modality for treating of sickle cell disease (SCD). Currently, three technologies are the most promising: expression of transgenic globin genes via a lentiviral vector, controlled mutation of the β-globin c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99050546e7bf19d3af32dc7f2c9a180f
https://doi.org/10.1016/j.transci.2022.103566
https://doi.org/10.1016/j.transci.2022.103566
Autor:
Yvette C, Tanhehco
Publikováno v:
Transfusion and Apheresis Science. 61:103532
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6245a003c20172265cf9a6fcffdb74db
https://doi.org/10.1016/j.transci.2022.103532
https://doi.org/10.1016/j.transci.2022.103532